Navigation Links
First Patient Enrolled in SARcode Bioscience's Pivotal Dry Eye Study of SAR 1118 Ophthalmic Solution
Date:9/14/2011

ented Edward Holland, MD, a cornea specialist from the Cincinnati Eye Institute and consultant to SARcode Bioscience.  "It is exciting to see this new molecular entity, which was specifically designed for ocular use, enter pivotal trials.  If the Phase 3 program is successful, this novel therapy will provide a much needed treatment option that not only alleviates the symptoms of dry eye, but also improves visual-related quality-of-life for patients suffering from this disease."

SARcode Bioscience anticipates completion of the OPUS-1 study and topline data in mid-year 2012.

About Dry Eye Disease

Dry eye disease is a prevalent and often chronic condition estimated to affect approximately 20 million people in the US.  This number is expected to grow substantially in the next decade due to an aging population and increased incidence of type 2 diabetes, both of which contribute to higher rates of this condition. Dry eye disease is among the most common disorders treated by ophthalmologists throughout the world, and has been shown to have a significant impact upon quality-of-life.  Dry eye varies in severity and etiology, and symptoms most commonly manifest as discomfort, visual disturbances, and tear film instability due to decreased quality or quantity of tears.  A major contributing factor towards the development of dry eye is inflammation caused by T-cell infiltration, proliferation and inflammatory cytokine production that can lead to reduction in tear film quality and ocular surface damage.

About SAR 1118

SAR 1118 is a potent novel small molecule lymphocyte function-associated antigen-1 (LFA-1) antagonist under investigation for a broad range of ocular inflammatory conditions including dry eye and diabetic macular edema. LFA-1 is member of the integrin family of adhesion receptors found on the surface of all leukocytes and represents a therapeutic target central to a number of inflammatory sti
'/>"/>

SOURCE SARcode Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... DRRX ) announced today financial results for the second ... loss was $5.5 million for the three months ended June ... and net loss of $5.5 million for the three months ... and investments of $37.8 million, compared to cash and investments ... 2015, we had $19.8 million in long term debt. ...
(Date:8/3/2015)... 2015 Par Pharmaceutical Companies, Inc. announced today ... August 7, 2015 at 9:00 a.m. EDT to review ... June 30, 2015.  Par is privately held and currently ... its filings with the Securities and Exchange Commission and ... by following the instructions at http://www.parpharm.com/financialinfo .  Par ...
(Date:8/3/2015)... , Aug. 3, 2015   ConvergeHEALTH ... pharmaceutical company Allergan plc is expanding ... and Intermountain Healthcare to include women,s ... ConvergeHEALTH,s OutcomesMiner analytics platform to generate real-world clinical ... "We look forward to expanding our ...
Breaking Medicine Technology:DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 3ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 4
... Calif. and SPRINGFIELD, Va. Oct. 29 Varian Medical Systems, ... Foundation has placed an order for five Varian TrueBeam™ systems ... CURE Foundation, which placed the order in September, plans to ... the U.S. East Coast during 2011.   ...
... Accuray Incorporated (Nasdaq: ARAY ), a global ... Creekside Cancer Care on their use of the CyberKnife ... in the world to install and begin treating patients with ... and clinicians at Creekside Cancer Care quickly reported that average ...
Cached Medicine Technology:CURE Foundation Selects Varian Medical Systems to Supply Radiotherapy Technology for Five New Cancer Centers 2CyberKnife® VSI™ System Expands Treatment Applications and Significantly Reduces Treatment Times 2CyberKnife® VSI™ System Expands Treatment Applications and Significantly Reduces Treatment Times 3CyberKnife® VSI™ System Expands Treatment Applications and Significantly Reduces Treatment Times 4
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and ... chin. Kybella is similar to deoxycholic acid, which occurs naturally in the body and ... options to treat this area of the body. These are invasive procedures and very ...
(Date:8/3/2015)... ... , ... A July 13 article from The Daily Mail titled "Jab ... That Can Last 'For Five Weeks'" discusses the use of stem cells to ... that harvesting stem cell-rich bone marrow from the hip, known as bone marrow stromal ...
(Date:8/3/2015)... Decatur, Illinois (PRWEB) , ... August 03, 2015 , ... ... (IBAM NA) effective July 31. , The acquisition includes all of IBAM NA’s ... the opportunity to have both, a robust regionally located business, as well as a ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... announced today that Joe Williams has joined its growing California employee benefits division. ... differentiated service model to his clients. Mr. Williams will be joining the newly ...
(Date:8/3/2015)... ... August 03, 2015 , ... Cambia Health Solutions has promoted ... the company’s Medicare and Federal Employee Programs (FEP) lines of business. , ... for members. In this role, Scott is responsible for overseeing the growth, finance ...
Breaking Medicine News(10 mins):Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2
... Highmark Blue Cross Blue Shield,United Concordia Companies, ... healthy smiles and lifestyles for Pittsburghers. Beginning at ... 19, a free clinic will,offer health information and ... For far too long, oral health has ...
... drug offers new hope , , FRIDAY, July 18 (HealthDay News) ... the search for treatments against Alzheimer,s disease. , In one ... The Lancet , an older drug called dimebon significantly improved ... failed to prevent the progression of Alzheimer,s -- even though ...
... 18 minSURG Corporation,producers of the TruFUSE(R) ... of minSURG International, Incorporated. The,international division has ... the TruFUSE procedure and products., CEO, ... Germany,Greece, South Korea, Netherlands, Singapore, Taiwan, Turkey ...
... is showing the benefits of resistance training in keeping older ... a postdoctoral research fellow with UQ and Blue Care, said ... age of 65 responded to resistance training. , "What ... improve muscle strength, power and functional performance." Dr Henwood said. ...
... the earliest events occurring immediately upon infection with HIV-I ... the immune system earlier than was previously understood. According ... the window of opportunity for successful intervention may be ... after transmission, as researchers had previously believed. , Appearing ...
... 2008 -- The legal and ethical issues facing medical ... than some other areas of medicine. Certain activities, such ... federal and state governments. Other activities, such as minimum ... state to state. , A number of distinguished ...
Cached Medicine News:Health News:Highmark Blue Cross Blue Shield, United Concordia and Catholic Charities Join Forces to Offer Free Health, Dental Services This Saturday 2Health News:Alzheimer's Research Brings Progress, Setbacks 2Health News:Alzheimer's Research Brings Progress, Setbacks 3Health News:Alzheimer's Research Brings Progress, Setbacks 4Health News:minSURG(TM) Corporation Launches International Division 2Health News:The benefits of a little resistance for older adults 2Health News:HIV conquers immune system faster than previously realized 2Health News:HIV conquers immune system faster than previously realized 3Health News:Legal and ethical issues in medical physics 2Health News:Legal and ethical issues in medical physics 3Health News:Legal and ethical issues in medical physics 4Health News:Legal and ethical issues in medical physics 5Health News:Legal and ethical issues in medical physics 6Health News:Legal and ethical issues in medical physics 7
The Vitatron Excellence SS+ lead series are endocardial silicone leads providing ease of handling and optimal pacing characteristics....
... The Vitatron Impulse II lead series ... designed to extend the longevity of ... efficient pacing. The high impedance of ... the small electrode surface, combined with ...
CapSure SP Novus endocardial, tined pacing leads provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but within an even smaller...
The Vitatron Slimtine S lead series are endocardial leads with an excellent history of reliability and optimal handling en pacing performance....
Medicine Products: